OVID

Ovid TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.60

+91.7% vs current

Most likely

Base case

50%

Probability

Target price

$2.70

+12.5% vs current

B-

Bear case

30%

Probability

Target price

$1.10

-54.2% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Primary-source tone is constructive on pipeline execution and balance-sheet strength, but coverage is thin and there is no fresh news flow in the packet. The stock still behaves like an event-driven clinical-stage name: upside depends on OV329/OV4071 readouts and disciplined capital use, while the recent financing only reduces, rather than removes, the execution burden.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-09-30eventOV4071 early human safety/PK updateHigh impact

Ovid says OV4071, its oral KCC2 direct activator, received HREC approval / CTN acknowledgement and dosed its first healthy-volunteer participant in May 2026; the next stock-moving step is an early safety and PK update that can show the program is progressing without tolerability setbacks [#SEC-8K-2026-03-18] [#PR-EARNINGS-2026-05-12].

2026-12-31eventOV329 patient-study transitionHigh impact

Management reported favorable 7 mg and 9 mg OV329 safety, tolerability, PK and exposure, and said the data support planned Phase 2 dose-confirmatory and proof-of-concept studies in refractory epilepsies and related indications [#SEC-8K-2026-03-18] [#PR-EARNINGS-2026-05-12].

2026-12-31catalystRunway supports multiple readoutsMedium impact

The March 2026 PIPE plus April warrant exercise lifted liquidity, and the company said cash, cash equivalents and marketable securities were $165.6 million at March 31, 2026 and that it expects to be well capitalized into 2029; that runway keeps multiple clinical shots alive while lowering the chance of an immediate dilutive raise [#PR-EARNINGS-2026-05-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology